Prevalence and presumptive triggers of localized bullous pemphigoid.
bullous pemphigoid
infection
localized bullous pemphigoid
prevalence
triggers in bullous pemphigoid
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
25
03
2021
received:
02
02
2021
accepted:
01
04
2021
pubmed:
18
5
2021
medline:
4
8
2021
entrez:
17
5
2021
Statut:
ppublish
Résumé
Bullous pemphigoid (BP) is an autoimmune skin disease, caused by autoantibodies to BP180 and/or BP230. While both these autoantigens are expressed in the entire skin, only some parts of the body become affected. Rare clinical observations indicate that BP may also manifest locally, usually following exposure to triggers. Here, we evaluated the occurrence and potential triggers of localized BP (LBP) in a cohort of 285 BP patients. Medical records of all BP patients hospitalized between 2009 and 2019 were reviewed. In 7/285 BP patients, a localized variant was identified. In 5/7 LBP patients, the disease remained local, while in 2/7 patients, an initial LBP subsequently spread. All cases were preceded by presumptive triggers, including previously described triggers and bacterial infections. Overall, LBP is rare. LBP, however, might be underdiagnosed and should thus be considered in the differential diagnosis, particularly when trigger factors preceded.
Identifiants
pubmed: 33998059
doi: 10.1111/1346-8138.15912
doi:
Substances chimiques
Autoantibodies
0
Autoantigens
0
Dystonin
0
Non-Fibrillar Collagens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1257-1261Informations de copyright
© 2021 The Authors. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Références
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381:320-32.
Mai Y, Nishie W, Sato K, Hotta M, Izumi K, Ito K, et al. Bullous pemphigoid triggered by thermal burn under medication with a dipeptidyl peptidase-IV inhibitor: a case report and review of the literature. Front Immunol. 2018;9:542.
Duschet P, Schwarz T, Gschnait F. Bullous pemphigoid after radiation therapy. J Am Acad Dermatol. 1988;18:441-4.
Dănescu S, Chiorean R, Macovei V, Sitaru C, Baican A. Role of physical factors in the pathogenesis of bullous pemphigoid: case report series and a comprehensive review of the published work. J Dermatol. 2016;43:134-40.
Sen BB, Ekiz Ö, Rifaioglu EN, Sen T, Atik E, Dogramaci A, et al. Localized bullous pemphigoid occurring on surgical scars. Indian J Dermatol Venereol Leprol. 2013;79:554.
Washio H, Hara H, Suzuki H, Yoshida M, Hashimoto T. Bullous pemphigoid on psoriasis lesions after UVA radiation. Acta Derm Venereol. 2005;85:561-3.
Vande Maele DM, Reilly JC. Bullous pemphigoid at colostomy site: report of a case. Dis Colon Rectum. 1997;40:370-1.
Batalla A, Peón G, De la Torre C. Localized bullous pemphigoid at urostomy site. Indian J Dermatol Venereol Leprol. 2011;77:625.
Saschenbrecker S, Karl I, Komorowski L, Probst C, Dähnrich C, Fechner K, et al. Serological diagnosis of autoimmune bullous skin diseases. Front Immunol. 2019;10:1974.
Koga H, Prost-Squarcioni C, Iwata H, Jonkman MF, Ludwig RJ, Bieber K, et al. Epidermolysis Bullosa Acquisita: the 2019 update. Front Med. 2018;5:362.
Hundt JE, Iwata H, Pieper M, Pfündl R, Bieber K, Zillikens D, et al. Visualization of autoantibodies and neutrophils in vivo identifies novel checkpoints in autoantibody-induced tissue injury. Sci Rep. 2020;10:4509.
Chang YT, Liu HN, Wong CK. Bullous pemphigoid-a report of 86 cases from Taiwan. Clin Exp Dermatol. 1996;21:20-2.
Thoma-Uszynski S, Uter W, Schwietzke S, Hofmann SC, Hunziker T, Bernard P, et al. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol. 2004;122:1413-22.
Ständer S, et al. Assessment of the healthcare costs for pemphigus and bullous pemphigoid patients in an academic center in Germany. Br J Dermatol. 2019;182(5):1296-7.